ABT
Abbott Laboratories
—
88.38 $
-0.1200 (%-0.14)
Previous Close: 88.5
Day Low₺87.76
Day High₺89.44
ABT: Abbott Laboratories Financials
ABT Income Statement
Total revenue
Net income
Gross margin TTM
55.51%
Operating margin TTM
18.16%
Net profit margin TTM
14.72%
Return on investment TTM
—
| Period end | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 44,328,000,000 | 41,950,000,000 | 40,109,000,000 | 43,653,000,000 |
| Operating income | 8,048,000,000 | 6,825,000,000 | 6,435,000,000 | 8,362,000,000 |
| Net income | 6,524,000,000 | 13,402,000,000 | 5,723,000,000 | 6,933,000,000 |
All line items
| Line item | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 44,328,000,000 | 41,950,000,000 | 40,109,000,000 | 43,653,000,000 |
| Cost of revenue | 19,721,000,000 | 20,625,000,000 | 20,072,000,000 | 21,330,000,000 |
| Gross profit | 24,607,000,000 | 21,325,000,000 | 20,037,000,000 | 22,323,000,000 |
| Research and development expenses | 2,955,000,000 | 2,823,000,000 | 2,719,000,000 | 2,852,000,000 |
| General and administrative expenses | 12,378,000,000 | 0 | 0 | 0 |
| Selling and marketing expenses | 0 | 0 | 0 | 0 |
| Selling, general and administrative expenses | 12,378,000,000 | 11,651,000,000 | 10,883,000,000 | 11,109,000,000 |
| Other expenses | 1,253,000,000 | 0 | 0 | 0 |
| Operating expenses | 16,586,000,000 | 14,474,000,000 | 13,602,000,000 | 13,961,000,000 |
| Cost and expenses | 36,280,000,000 | 35,099,000,000 | 33,674,000,000 | 35,291,000,000 |
| Net interest income | -111,000,000 | -259,000,000 | -313,000,000 | -132,000,000 |
| Interest income | 230,000,000 | 344,000,000 | 385,000,000 | 183,000,000 |
| Interest expense | 341,000,000 | 603,000,000 | 698,000,000 | 315,000,000 |
| Depreciation and amortization | 2,746,000,000 | 3,218,000,000 | 3,243,000,000 | 3,267,000,000 |
| EBITDA | 11,553,000,000 | 10,834,000,000 | 10,605,000,000 | 11,888,000,000 |
| EBIT | 8,807,000,000 | 7,616,000,000 | 7,362,000,000 | 8,621,000,000 |
| Non-operating income (excl. interest) | -759,000,000 | -765,000,000 | -927,000,000 | -259,000,000 |
| Operating income | 8,048,000,000 | 6,825,000,000 | 6,435,000,000 | 8,362,000,000 |
| Total other income/expenses (net) | 418,000,000 | 188,000,000 | 229,000,000 | -56,000,000 |
| Income before tax | 8,466,000,000 | 7,013,000,000 | 6,664,000,000 | 8,306,000,000 |
| Income tax expense | 1,942,000,000 | -6,389,000,000 | 941,000,000 | 1,373,000,000 |
| Net income from continuing operations | 6,524,000,000 | 13,402,000,000 | 5,723,000,000 | 6,933,000,000 |
| Net income from discontinued operations | 0 | 0 | 0 | 0 |
| Other adjustments to net income | 0 | 0 | 0 | 0 |
| Net income | 6,524,000,000 | 13,402,000,000 | 5,723,000,000 | 6,933,000,000 |
| Net income deductions | 0 | 0 | 0 | 0 |
| Bottom line net income | 6,524,000,000 | 13,402,000,000 | 5,723,000,000 | 6,933,000,000 |
| EPS | 4 | 8 | 3 | 4 |
| Diluted EPS | 4 | 8 | 3 | 4 |
| Weighted average shares outstanding | 1,747,000,000 | 1,731,698,000 | 1,734,076,358 | 1,753,000,000 |
| Weighted average diluted shares outstanding | 1,747,000,000 | 1,748,000,000 | 1,749,000,000 | 1,764,000,000 |